melphalan and Primary-Ovarian-Insufficiency

melphalan has been researched along with Primary-Ovarian-Insufficiency* in 2 studies

Other Studies

2 other study(ies) available for melphalan and Primary-Ovarian-Insufficiency

Article	Year
Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone marrow transplantation, 1998, Volume: 22, Issue:10 We studied pubertal status and ovarian function in 21 girls aged 11-21 years who had earlier received 1.2-13 years (median 7 years) high-dose chemotherapy and autologous BMT without TBI for malignant tumors. Ten of them were given busulfan (600 mg/m2) and melphalan (140 mg/m2) with or without cyclophosphamide (3.6 g/m2). Eleven others did not receive busulfan. Twelve girls (57%) had clinical and hormonal evidence of ovarian failure. Among nine others who had completed normal puberty, six had normal gonadotropin levels, one had elevated gonadotropin levels and two had gonadotropin levels at the upper limit of normal. The 10 girls who received busulfan all developed severe and persistent ovarian failure. High-dose busulfan is therefore a major cause of ovarian failure even when given in the prepubertal period. These findings emphasize the need for long-term endocrine follow-up of these patients in order to initiate estrogen replacement therapy. Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Estradiol; Female; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Immunosuppressive Agents; Luteinizing Hormone; Melphalan; Neoplasms; Ovarian Function Tests; Ovary; Primary Ovarian Insufficiency; Puberty, Delayed; Survivors; Transplantation Conditioning; Transplantation, Autologous	1998
Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy. Leukemia & lymphoma, 1993, Volume: 10, Issue:4-5 Currently no treatment has proved successful in inducing ovarian steroidogenic and/or gametogenic recovery in patients with haematological malignancies treated by cytotoxic chemotherapy once biochemical failure becomes manifest i.e., when FSH levels exceed 40 IU/L. This paper reports two such cases with classical biochemical ovarian failure in which ovarian function was induced by brief stimulation with Human Menopausal Gonadotrophin (HMG). Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Follicle Stimulating Hormone; Hodgkin Disease; Humans; Leukemia, Myelomonocytic, Acute; Luteinizing Hormone; Melphalan; Menotropins; Ovulation Induction; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy, Multiple; Primary Ovarian Insufficiency; Remission Induction; Teniposide; Thioguanine; Vincristine	1993

Article

Year

Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure.

Bone marrow transplantation, 1998, Volume: 22, Issue:10

We studied pubertal status and ovarian function in 21 girls aged 11-21 years who had earlier received 1.2-13 years (median 7 years) high-dose chemotherapy and autologous BMT without TBI for malignant tumors. Ten of them were given busulfan (600 mg/m2) and melphalan (140 mg/m2) with or without cyclophosphamide (3.6 g/m2). Eleven others did not receive busulfan. Twelve girls (57%) had clinical and hormonal evidence of ovarian failure. Among nine others who had completed normal puberty, six had normal gonadotropin levels, one had elevated gonadotropin levels and two had gonadotropin levels at the upper limit of normal. The 10 girls who received busulfan all developed severe and persistent ovarian failure. High-dose busulfan is therefore a major cause of ovarian failure even when given in the prepubertal period. These findings emphasize the need for long-term endocrine follow-up of these patients in order to initiate estrogen replacement therapy.

Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Estradiol; Female; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Immunosuppressive Agents; Luteinizing Hormone; Melphalan; Neoplasms; Ovarian Function Tests; Ovary; Primary Ovarian Insufficiency; Puberty, Delayed; Survivors; Transplantation Conditioning; Transplantation, Autologous

1998

Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.

Leukemia & lymphoma, 1993, Volume: 10, Issue:4-5

Currently no treatment has proved successful in inducing ovarian steroidogenic and/or gametogenic recovery in patients with haematological malignancies treated by cytotoxic chemotherapy once biochemical failure becomes manifest i.e., when FSH levels exceed 40 IU/L. This paper reports two such cases with classical biochemical ovarian failure in which ovarian function was induced by brief stimulation with Human Menopausal Gonadotrophin (HMG).

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Follicle Stimulating Hormone; Hodgkin Disease; Humans; Leukemia, Myelomonocytic, Acute; Luteinizing Hormone; Melphalan; Menotropins; Ovulation Induction; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy, Multiple; Primary Ovarian Insufficiency; Remission Induction; Teniposide; Thioguanine; Vincristine

1993